Antiviral agents, a diverse class of pharmaceutical compounds, play a crucial role in combating viral infections by targeting specific stages of the viral life cycle. Nucleoside/nucleotide analogs, such as acyclovir and tenofovir, interfere with viral genome replication, inhibiting the synthesis of viral DNA or RNA. Protease inhibitors, like ritonavir and lopinavir, disrupt the maturation of viral proteins, particularly vital in managing retroviruses like HIV. Neuraminidase inhibitors, exemplified by oseltamivir, are instrumental in treating influenza by preventing the release of new virions from infected cells. The advent of RNA-based therapies, including RNA interference (RNAi) and CRISPR technologies, holds promise in providing precise tools to target and silence viral genetic material. Antiviral vaccines, exemplified by those against influenza and hepatitis, serve as preventive measures, stimulating the immune system to recognize and combat specific viral antigens. As the field advances, nanotechnology and immunotherapies emerge as innovative approaches, paving the way for more effective antiviral interventions.
Title : The role of the humoral innate immune system in evasion of streptococcus pyogenes infections
Francis J. Castellino, University of Notre Dame, United States
Title : Global environmental changes and mosquito-borne diseases in coastal areas
Ranjan Ramasamy, IDFISH Technology, United States
Title : The impact of global antibiotic resistance on the healthcare system, public health, environment and society
Reza Nassiri, Michigan State University, United States
Title : Current topics of adult COVID-19, Influenza, and RS virus patients in Japan
Seki Masafumi, Saitama Medical University International Medical Center, Japan
Title : Novel nanotechnology and its potential applications
Stephen Hsu, Augusta University, United States
Title : 2000 years of pandemics: Past, present and future
Claudia Ferreira, Biophytis Sorbonne, France